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ABSTRACT 
On the basis of epidemiological studies, infection was suggested to play a role in the etiology 
of human cancer. While for some cancers such a role was indeed demonstrated, there is no 
direct biological support for the role of viral pathogens in the pathogenesis of childhood 
leukemia. Using a novel bioinformatic tool, that alternates between clustering and standard 
statistical methods of analysis, we performed a "double blind" search of published gene 
expression data of subjects with different childhood ALL subtypes, looking for unanticipated 
partitions of patients, induced by unexpected groups of genes with correlated expression. We 
discovered a group of about thirty genes, related to the interferon response pathway, whose 
expression levels divide the ALL samples into two subgroups; high in 50, low in 285 patients. 
Leukemic subclasses prevalent in early childhood (the age most susceptible to infection) are 
over-represented in the high expression subgroup. Similar partitions, induced by the same 
genes, were found also in breast and ovarian cancer but not in lung cancer, prostate cancer and 
lymphoma. About 40% of breast cancer samples expressed the "interferon- related" signature. 
It is of interested that several studies demonstrated MMTV-like sequences in about 40% of 
breast cancer samples. Our discovery of an unanticipated strong signature of an interferon 
induced pathway provides molecular support for a role for either inflammation or viral 
infection in the pathogenesis of childhood leukemia as well as breast and ovarian cancer.  
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INTRODUCTION 
Recent years have witnessed accelerated improvement of gene expression measurement 
techniques, and a rapid growth of their usage, in particular for studies of malignancies. These 
technological advances were not accompanied by a similar rate of improvement in analysis 
methods (Ross et al., 2003; Yeoh et al., 2002). The present publication has two distinct aims. 
First, we demonstrate that when novel methods of analysis are applied to data that have been 
previously published and studied, it is possible to discover important molecular pathways that 
have completely eluded previous studies (Armstrong et al., 2002; Golub et al., 1999; Ross et 
al., 2003; Yeoh et al., 2002), that employed  standard, commonly used methods  for analysis of 
gene expression data. Our second goal is to present the discovery of a robust signature of a 
group of interferon inducible genes (IIG) associated with childhood leukemia and with other 
cancers, and to discuss its intriguing biological and clinical implications.  
 
As has been discussed in several publications (Califano et al., 2000; Cheng & Church, 2000; 
Getz et al., 2000; Ihmels et al., 2002; Tanay et al., 2002), one of the main strengths of the 
modern gene expression technology also generates  a considerable difficulty in interpreting the 
results. The strength is the holistic view achieved by measuring the expression levels of a very 
large number of genes in a single experiment. Typically, however, the expression signatures of 
an overwhelming majority of these genes are not related directly to the biological process (e.g. 
cancer) one wishes to study; in fact, most of the measured genes give rise to a very noisy 
background, from which one tries to extract the relatively weak signal of correlated activity of 
a small but relevant group of genes. A straightforward way to zero in on a relevant subset of 
genes is by means of a supervised filtering step – for example, identification of genes whose 
expression differentiates two or more groups of samples known to be genetically or clinically 
different. However, such a step can never lead to the discovery of unexpected partitions 
induced by genes whose role has not been previously anticipated. An alternative is provided by 
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a family of methods (Califano et al., 2000; Cheng & Church, 2000; Getz et al., 2000; Ihmels et 
al., 2002; Tanay et al., 2002) that search for subgroups of genes and samples that satisfy certain 
conditions,, in an unsupervised manner. In particular, the Coupled Two-Way Clustering 
(CTWC, (Getz et al., 2000) clusters all genes as the first step, to identify correlated groups of 
genes; these gene-clusters are then used, one at a time, to probe and analyse the subjects. We 
use CTWC as our starting step, but deviate from this method in that the search is refined by a 
combination of more standard statistical tests (rather than continuing by unsupervised 
clustering), to zero in on an apparently interesting group of genes. Here we show that this 
mixture of supervised and unsupervised methodologies benefits from the advantages inherent 
to both methodologies and can lead to the discovery of biologically significant gene signatures.  
 
 The possible role of dysregulated immune or inflammatory response in the 
development of human cancer, and in particular its association with infectious agents, was 
suggested for many years. Several human lymphoid malignancies are associated with 
infectious agents: Burkitt’s lymphoma with Epstein-Barr virus (Henle & Henle, 1966), ATL 
with HTLV-I (Poiesz et al., 1980), body-cavity lymphoma with human herpes 8 (Mele et al., 
2003), B-cell non-Hodgkin Lymphoma with hepatitis C (Mele et al., 2003) and gastric MALT 
lymphoma with Helicobacter Pylori (Peek & Blaser, 2002).  
  It has long been suspected that common childhood infections contribute to the etiology 
of childhood leukemia, in particular ALL. The infectious etiology hypothesis has been 
proposed by two distinct but complementary theories. The Kinlen theory (Kinlen, 1995), based 
on transiently increased rates of leukemia in geographical clusters, suggests that population 
mobility and mixing result in infection occurring in susceptible, previously unexposed 
individuals. Several epidemiological studies supported the population mixing theory (Kinlen & 
Balkwill, 2001; Koushik et al., 2001). The alternative “delayed infection” hypothesis(Greaves, 
1988; Greaves, 1997; Greaves & Alexander, 1993) focuses on the timing of common 
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childhood infections and claims that some leukemia cases, mainly of the common B cell 
precursor subtype of ALL (cALL), are associated with a lack of exposure in infancy and a 
resultant failure of normal immune modulation. Dysregulated immune response upon delayed 
exposure to microbial infection is suggested to contribute to leukemogenesis. Studies in 
identical twins with leukemia (Ford et al., 1998; Wiemels et al., 1999), analysis of archived 
neonatal blood spots and screening of cord blood samples (Gale et al., 1997; Wiemels et al., 
1999) indicate that cALL is frequently initiated by chromosomal translocations and non-
disjunctions that occur prenatally, but requires a second “hit” to produce  leukemia. The 
dysregulated response to infection is suggested to provide, probably indirectly, proliferative or 
apoptotic stress to the bone marrow, leading to the additional decisive “hit”. The exposure is 
predicted to occur proximally to clinical disease, suggesting that a “smoking gun” can be 
identified when leukemia cell samples are studied. Despite intense research (MacKenzie et al., 
2001; MacKenzie et al., 1999), no direct biological  evidence, such as identification of 
microbial sequences, was found. Similarly, no epidemiologic data linking specific pathogens to 
ALL development were described. Several anecdotal reports described rare cases of ALL 
diagnosis preceded by a preleukemic phase known as pre-ALL in association with EBV or 
parvo B19 infection (Hasle et al., 1995; Tabori et al., 2001). 
 We describe here the identification of a gene expression signature in a subset of the 
patients suggestive of a deregulated immune response to some pathogen. We show that this 
signature occurs with highest frequency (one third) in the hyperdiploid ALL cases and as a 
smaller fraction in the other childhood leukemia subtypes. The finding of this gene expression 
profile in childhood leukemia, in particular in those cases that are overrepresented in the early 
childhood cALL peak, supports the role of an infectious agent, most probably a virus, in the 
pathogenesis of leukemia.  
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We looked for the same gene expression signature in a variety of data-sets of other human 
cancers. While in the majority of cancer samples no significant overexpression of the IIG was 
observed, it was detected in 40% of breast cancer and 20% of ovarian cancer samples. Indeed, 
some epidemiological studies have previously suggested a role for infection in the 
pathogenesis of ovarian (Ness et al., 2003) and breast (Ford et al., 2003) tumors. Additionally, 
molecular studies identified mouse mammary tumor virus-like sequences in about 40% of 
breast cancer samples (Ford et al., 2003; Wang et al., 1995). The "interferon signature" may 
reflect the activation of this pathway in the transformed cells themselves. Alternatively, it can 
reflect the response of the cancer cells to non-malignant cells of the immune system. 
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RESULTS 
 
Analyzing the data of Yeoh et al (Yeoh et al., 2002).  
Our aim was class discovery: to identify new partitions of the samples, into sub-groups with no 
previously known common label, on the basis of the expression profiles of a group of genes 
with correlated expression levels. To this end we used the CTWC method (see methods 
section).  The expression levels of 3000 probe-sets that passed a variance filter were used in 
this analysis. We applied the algorithm on each of the ALL subtypes separately, in order to 
avoid 'inter-subtype' noise. ALL subtypes with large numbers of samples were the first to be 
analyzed. When we applied the algorithm on TEL-AML1, a group of 16 probe-sets representing 
15 genes (Table 1) separated the TEL-AML1 subtype very clearly into two sub-groups (Figure 
a): in 8 TEL-AML1 samples these probe-sets had high expression levels whereas in the 
remaining 71 samples their expression level was relatively low. The distinct group of 8 
samples shared no clinical label (such as same protocol of treatment or same prognosis). 
Strikingly, the majority (12 of 15) of the differentiating genes were interferon inducible genes 
(IIG). This constitutes step (i) of our analysis.   
 Next, in step (ii), we refined the list of these genes, using supervised analysis.  We took 
the separation into the two groups of 8 versus 71 samples as "ground truth" and searched for 
genes that differentiate between these two groups. This search was performed on an extended 
set of 6500 genes. 184 probe-sets passed the TNoM as differentiating, with p-values below 
0.05. To overcome the problem of multiple comparisons we applied the FDR method; 23 
probe-sets, representing 19 genes, were identified as separating at an FDR level of 5%. The 
practical meaning of this statement is that out of these 23 probe-sets we expect about one to be 
a false positive, present due to random fluctuations. 
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The next step, (iii), of our iterative refinement process was again unsupervised; we used the 
expression levels of the 23 probe-sets found in step (ii), to characterize all samples, and 
clustered them using SPC. This way we identified a group of 50 samples, selected from all the 
ALL subtypes; these 50 have high expression levels of the 23 probe-sets (Figure 2). This group 
of samples consists mainly of hyperdiploid>50 but contains almost all other subtypes as well 
(Table 2). The hyperdiploid>50 subtype was significantly over-represented among the 50 
samples with high expression; no other clinical label, specific to these samples, was found. 
Finally, to complete the refinement process, supervised analysis was performed again in step 
(iv), using TNoM on 6500 probe-sets, revealing 28 genes that most significantly separate the 
new sub-group of 50 samples from the remaining 285 samples (see Table 1).  
 
Each of the four steps yielded its own list of separating probesets (genes). Although not 
identical, these gene lists have significant overlaps, which can also be inferred from Table 1. 
Out of the total 30 of known genes (whose symbols are given in the Table), 17 are known to be 
induced by interferon; most of these have never been associated with leukemia. 
  
Analysis of other datasets (Armstrong et al., 2002; Bhattacharjee et al., 2001; Golub et al., 
1999; Ramaswamy et al., 2001; Rozovskaia et al., 2003; Shipp et al., 2002; Singh et al., 2002; 
Staunton et al., 2001; van 't Veer et al., 2002; Welsh et al., 2001; Welsh et al., 2001).  
 
We now turned to search for other types of cancer in which a similar finding may hold; we 
tested whether we can find a sub-division of samples in other datasets on the basis of the 
expression levels of genes from the same pathway. However, in each of the following datasets 
we had to use a different subgroup of the separating genes, since some genes did not appear in 
these datasets and others had too many missing values. We ran the SPC algorithm for each 
dataset, using the appropriate subgroups of our gene list. Our aim was to find a distinct group 
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of samples, in which these genes were overexpressed. In addition, we checked the sample 
labels in order to find common clinical indicators, shared by the members of the selected 
subgroup.    
 We applied the same method of analysis to the more recent leukemia data of the same 
group (Ross et al., 2003; Yeoh et al., 2002), where the Affymetrix HG-U133 microarrays, 
containing 45,000 probesets representing 33,000 genes, was used on a much smaller number of 
samples, 132 representative cases. Although the genes and their representation on these 
microarrays are different; we did find a subset of the IIG (14 genes) that appears on both chips 
and clearly identifies a small subgroup (18% of the samples) with high IIG expression levels. 
Among these the hyperdiploid>50 samples were very significantly over-represented.  
            We then turned to analyze the leukemia data (Table 3) of Golub et al.(Golub et al., 
1999), Armstrong et al.(Armstrong et al., 2002) and Rozovskia et al.(Rozovskaia et al., 2003). 
In each of these datasets we also found clear subgroups (containing about 10% of the samples), 
with overexpressed levels of these genes. Again, no common label was shared by the subgroup 
members.  
 
           Next, we ran SPC on datasets of other types of cancer (Table 3): (lymphoma(Shipp et 
al., 2002), prostate(Singh et al., 2002; Welsh et al., 2001) various tumors (Ramaswamy et al., 
2001; Staunton et al., 2001),  ovary(Welsh et al., 2001) , lung(Bhattacharjee et al., 2001) and 
breast(van 't Veer et al., 2002)). We found very small or negligible sub-groups of samples that 
co-expressed the unique sub-group of IIG in the lymphoma, prostate and lung cancers. 
Analysis of the data published by Ramaswamy et al.(Ramaswamy et al., 2001), which contains 
samples from various types of cancer, revealed a small sub-group, 7 out of 280, that also 
contains samples from other types of cancer, but mainly from leukemia, lymphoma and even 
from normal peripheral blood samples. In the lung cancer dataset of 
Bhattacharjee(Bhattacharjee et al., 2001), a clear separation of ~1.5% of the samples was 
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detected. The most significant signal came from the breast cancer data of Van't Veer et al.(van 
't Veer et al., 2002), where 40% of the samples overexpressed these genes (Figure 3), and  the 
ovary cancer dataset of Welsh(Welsh et al., 2001), in which the interferon-related genes were 
overexpressed in about 20% of the samples.  
 
Confirmation of Differential Gene Expression by RQ-PCR 
For an independent verification of this bioinformatic analysis we have examined by 
RQ-PCR the expression of two of the interferon inducible genes IRIFT4 and IRF7 (table 1) in 
RNA derived from diagnostic bone marrow samples of 63 children with B cell precursor ALL. 
These patients were not part of the cohort included in the original microarray analysis of Yeoh 
and al. Despite the limitations imposed by the analysis of only two genes, using SPC, we have 
identified a cluster comprised from 10 patients with significantly higher expression of both 
genes. Interestingly, the average age of these patients was 4.45 years at the time of diagnosis, 
lower than 7.73, the average age in the low expression levels subgroup. The p-value for this 
age difference, assigned by the Student t test, was P = 0.011. All patients but one in the small 
sub-group are in the age range of 2 to 6. There were no statistical significant differences in 
other clinical parameters (although this is a too small group to identify survival patterns). Thus, 
an analysis of gene expression by a different methodology (RQ-PCR) in an independent set of 
patients identified a similar cluster of interferon inducible genes, in a similar fraction (15.8%) 
of patients with B cell precursor ALL.  
 
 
 
DISCUSSION 
 In this work we analyzed recently published gene expression data of different subtypes 
of childhood ALL by means of an unsupervised approach, using the SPC and CTWC clustering 
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methods in order to search for a set (cluster) of genes, whose expression profile separates the 
samples into two (unanticipated) distinct groups. Such a gene cluster was found, and extended 
using the TNoM supervised method. The search for the characteristic gene set was performed 
in a totally unprejudiced "blind" way regarding either the separating gene set or the resulting 
partition of the samples. Surprisingly, a special set of genes was found to be highly expressed 
in a small minority (0-14%) of samples of the various leukemia subtypes, and in a relatively 
high percentage (37%) of the hyperdiploid (>50) ALL subgroup that constitutes a large part of 
the cases in the early childhood peak of leukemia. 17 out of the 30 known genes that appear in 
Table 1 are interferon inducible genes. These include signal transducer and activator of 
transcription 1 (STAT1) and interferon regulatory factor 7 (IRF7), both involved in signal 
transduction downstream to interferon receptors, as well as many interferon alpha induced 
proteins such as interferon induced protein 44, interferon induced transmembrane protein 3, 
interferon induced protein 35, 2’5’-oligoadenylate synthetase 1 and 2, myxovirus resistance 1 
interferon-inducible protein 78 and adenosine deaminase RNA specific. Interferon gamma-
induced proteins such as protein 30 and interferon gamma-induced transcription factor 3 were 
also found in the special gene cluster. Interestingly, several ubiquitin-conjugating enzymes 
such as E2L6 and E2A and proteasome system components such as activator subunit 2 (PA28 
beta), some of them known to be induced by interferon, were also present in the cluster. Such 
proteins are involved in the generation of antigenic peptides that are presented to CD8+ T cells 
by MHC class I molecules. Taken together, many genes relevant to the immune response were 
found to be present in the special cluster of IIG that are highly expressed in the hyperdiploid 
leukemia variant. Of great interest is the presence of apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like 3G (APOBEC3G) in the interferon related gene cluster. This enzyme 
was shown lately to confer antiretroviral defense against HIV and other retroviruses through 
lethal editing of nascent reverse transcripts)Mangeat et al., 2003; Zhang et al., 2003(. 
Hypermutation by editing mediated by this enzyme was shown to be an innate defense 
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mechanism against retroviruses. One may speculate that the expression of this gene is an 
indication for retrovirus involvement in childhood leukemogenesis.  
 
The existence of the IIG cluster in B-cell precursor childhood leukemia was confirmed 
in independent cohort using RQ-PCR. This RQ-PCR validation is preliminary and therefore the 
size of the examined gene set was limited.  We plan to extend this analysis to a larger cohort 
with additional genes included in the IIG cluster.  
 
 The search for the IIG cluster in other datasets of several malignant diseases (Table 3) 
indicates that in other datasets of leukemia about 10% of the samples expressed the special 
gene set. In lymphomas, prostate, lung and datasets of a variety of tumors none or a very low 
percentage of the samples expressed the set. The exceptions are the dataset of 49 ovarian 
cancer samples and 96 breast cancer samples; A subset of ~20% of the ovarian cancers and 
~40% of the breast cancers overexpressed the gene set. It is of interest that some epidemiologic 
studies suggested a role for infection in the pathogenesis of other cancers, in addition to 
leukemia, among them both ovarian (Ness et al., 2003) and breast (Ford et al., 2003) tumors. 
The lack of the IIG set in the majority of non-leukemic samples supports the significance of the 
finding in the leukemic samples.  
 
In particular, the prominent appearance of hyperdiploid leukemic samples (that occur in 
early childhood, when viral infection is most likely to occur) and the significant lower age of 
the sub-group of patients from the independent cohort strengthen the hypotheses of Greaves 
and Kinlen. 
 
 The finding that about 40% of breast cancer samples displayed the ‘infection 
associated’ gene signature is of special significance.  Retrovirus-like particles were 
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demonstrated in a breast cancer cell line (Keydar et al., 1984)  and MMTV-like gene sequences 
were detected by PCR in about 40% of  breast cancer samples in several studies (Ford et al., 
2003; Wang et al., 1995). Interestingly, the percentage of cases where retroviral gene 
sequences were identified is very similar to the percentage of cases where the interferon gene 
signature was identified (~ 40%).  The experiment to be done is to look at the same tumor 
samples for both interferon-associated gene expression and for the MMTV-like gene 
sequences,   
 The samples with high expression of the IIG constitute a minority of the malignant 
samples. In the leukemia hyperdiploid subgroup only one third of the samples were positive 
and in the breast cancer cases 40% were positive. Several explanations can be suggested for 
this finding. First, infection can represent only one type of causative factor or “second hit” 
event and other mechanisms may operate in the rest of the cases. Second, the role of infection 
may be indirect, via the dysregulated immune response. Under such a scenario the infectious 
agent can contribute to leukemogenesis in a transient “hit and run” fashion and its fingerprints 
may not be found at the time of diagnosis. In addition, it can be expected that in different 
populations the involvement of viruses can vary, due to environmental and genetic factors, as 
was recently suggested in the case of differential expression of MMTV-like sequences in breast 
cancer patients from Australian and Vietnamese origin (Ford et al., 2003).  
  
 An immune response to viral infection is by no means the only reasonable explanation 
for the IIG signature discovered in these cancer samples.  Since interferons are known to be 
produced by a variety of inflammatory cells (Colonna et al., 2002; Dalgleish & O'Byrne, 2002; 
Ernst, 1999) the induction of interferon responsive genes may reflect the degree of tumor 
inflammation. This may hold particularly for solid tumors, rather than leukemias. Tumor 
infiltrating lymphocytes are commonly found in breast and ovarian cancers (Georgiannos et al., 
2003; Liyanage et al., 2002; Nzula et al., 2003; Reome et al., 2004). Thus the upregulation of 
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interferon inducible genes in a fraction of specific tumors may reflect the response of the 
cancer cells to interferon secreted by host immune cells. Since some of the genes presented in 
the IIG signature are associated with growth inhibitory properties (Chawla-Sarkar M, 2003; 
Sangfelt, 2001; Wall et al., 2003; Zhang et al., 2003) it is tempting to speculate that this 
signature may be associated with improved prognosis. Accordingly, hyperdiploid ALL is 
associated with the best response to chemotherapy and increased rate of apoptosis (Ito et al., 
1999; Pui CH, 2004). Interestingly it has been recently demonstrated that the presence of 
intratumural T-lymphocytes correlated favorably with survival of patients with ovarian cancer 
(Zhang et al., 2003). 
 
 A minority of the genes in the IIG signature e.g STAT1 and IFIT4 may be induced by 
other cytokines or by retinoic acid or chemotherapy (Ihle & Kerr, 1995; Yu et al., 1997). 
However, most of the genes present in this signature are known to be induced prinipally by 
interferons. Also all the analyzed databases included only diagnostic samples prior to exposure 
to chemotherapy. Thus our finding, of a highly expressed “interferon cluster”, combined with 
the epidemiological evidence, most likely implies an immune response, either to viral infection 
or to the tumor cells, leading to interferon secretion, activation of interferon receptors and 
STAT signaling, resulting in the activation of many interferon regulated genes. Nevertheless, 
another possibility, that the pathway was activated by a mutation in the cancer cells, 
independent of a response to the host environment , cannot be completely ruled out. 
Interestingly, three interferon receptor genes are located on chromosome 21, a chromosome 
that is always amplified in hyperdiploid leukemia (Heerema et al., 2000). The role of aberrant 
STAT signaling (mainly STAT3 but not the interferon induced STAT1) and constitutive STAT 
activation in leukemia is the subject of several recent publications (Benekli et al., 2003). It is 
unclear whether constitutive STAT activation itself is the cause or the result of a transforming 
process.  
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We have demonstrated that applying a novel blind unsupervised subgroup discovery approach 
to publicly available gene expression databases allows identification of previously 
unrecognized biologically meaningful molecular signatures. Specifically we identified a set of 
interferon- regulated genes characterizing mainly the hyperdiploid lymphoblastic leukemia, 
breast cancer and ovarian cancers (and, possibly, in other types of cancer that were not studied 
here). The various hypotheses raised by the finding of this novel gene signature in cancers can 
be tested experimentally by the research groups that published the original gene expression 
datasets. For example, it could be interesting to examine the interferon levels in stored serum 
from patients with childhood ALL or to correlate the presence of retroviral particles or the 
degree of infiltration of lymphocytes in breast cancer specimens with the interferon induced 
genes' signature, as well as searching for activating mutations or polymorphisms in interferon 
receptor genes in patients with hyperdiploid childhood ALL.  Clearly, this finding generates 
several biologically testable hypotheses whose potential implications on diagnosis, therapy and 
prevention of childhood leukemia, breast cancer and other malignancies are evident.  
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MATERIALS AND METHODS  
Patients and Specimens.  
Microarray Data. There are several publicly available gene expression datasets on leukemia 
(Armstrong et al., 2002; Golub et al., 1999; Rozovskaia et al., 2003; Yeoh et al., 2002) We 
analyzed the data of Yeoh et al.(Yeoh et al., 2002), that tested diagnostic bone marrow samples 
from 327 ALL patients using Affymetrix U95A microarrays containing 12,533 probe sets. The 
samples were collected at the time of discovery of the disease, prior to administering any 
therapy. Expression levels were measured for 335 samples of bone marrow and peripheral 
blood representing several different ALL subtypes (T-ALL, E2A-PBX1, BCR-ABL, TEL-AML1, 
MLL, hyperdiploid >50 chromosomes, hyperdiploid 47-50 and hypodiploid). We expanded the 
analysis to other publicly available datasets of leukemia (Armstrong et al., 2002; Golub et al., 
1999; Rozovskaia et al., 2003) and other cancers including: lymphoma (Shipp et al., 2002), 
prostate (Singh et al., 2002; Welsh et al., 2001), ovary (Welsh et al., 2001), lung (Bhattacharjee 
et al., 2001) and breast (van 't Veer et al., 2002).  
Quantification by real time quantitative PCR (RQ-PCR): The expression of IRF7 and 
IRFIT1 was quantified in RNA derived from diagnostic bone marrow samples given with an 
informed consent by 63 children with B cell precursor ALL. RNA isolation, cDNA synthesis 
and RQ-PCR were performed as described by us (U.O) before (Akyerli et al., 2005). For every 
sample the amount and the quality of RNA was normalized by dividing by the corresponding 
arrythmetic median of Beta 2 microglobin and c-Abl “housekeeping” genes. Primer sequences 
(5’-3’) were: IRFIT1: forward CACATGGGCAGACTGGCAG, reverse 
GCGGAAGGGATTTGAAAGCT; IRF7 forward TCCCCACGCTATACCATCTACC, reverse 
CAGGGTTCCAGCTTCACCAG;  
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Beta–2-Microglobulin (B2M) forward TGCCGTGTGAACCATGTGAC,  reverse 
ACCTCCATGATGCTGCTTACA; c-ABL forward CCCAACCTTTTCGTTGCACTGT, 
reverse  CGGCTCTCGGAGGAGACGTAGA. 
 
Microarray data analysis 
Preprocessing and filtering the data. We worked with an expression matrix organized in 335 
columns (samples) and 12,533 rows (genes). Each value in the matrix is the expression level of 
a certain gene in a certain patient. Rows (genes) in which more than 20% of the values were 
lower than some threshold (T=10) were removed. After this filtering 6,653 genes remained. In 
these rows the values that were lower than T were replaced by estimates based on the values of 
the 13 nearest neighbors' genes(Troyanskaya et al., 2001). Next, logarithm (base 2) of each 
entry was taken, and the genes were filtered on the basis of their variation across the samples. 
Two sets, of 3000 and of 6500 genes were chosen, on the basis of their standard deviations, for 
the Coupled-Two Way Clustering (CTWC) step and for the Threshold Number of 
Misclassifications (TNoM) test, respectively.  Similar procedures were followed for each of the 
additional data-sets. 
Unsupervised analysis: Clustering. In order to separate the ALL samples into unanticipated 
sub-groups, we searched for a cluster (e.g. correlated set) of genes with a distinct expression 
profile in one part of the samples, and another profile in the other part. Since hypothesis testing 
can not reveal unexpected partitions, unsupervised techniques, such as clustering, are more 
suited for such a task.  The CTWC  method (Getz et al., 2000) focuses on correlated groups of 
genes, one group at a time.  Relevant subsets of genes and samples are identified by means of 
an iterative process, which uses at each iteration level stable gene and sample clusters that were 
generated at the previous step. The ability to focus on stable, statistically significant clusters 
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that were generated by the underlying clustering operation is essential for the CTWC method. 
Since Superparamagnetic Clustering (SPC) (Blatt et al., 1996) provides a reliable stability 
index, it is the method of choice to use in the CTWC scheme. The SPC  algorithm is based on 
the physical properties of  inhomogeneous ferromagnets (Blatt et al., 1996; Blatt et al., 1997; 
Getz et al., 2000). The unsupervised CTWC step yields a list (cluster) of genes, whose 
expression levels separate the samples into two groups, which constitute the starting point of 
the next, supervised steps of the analysis. 
Supervised analysis. We used supervised methods in order to expand and refine the list of 
genes that was obtained by the unsupervised CTWC step. Using hypothesis testing 
(TNoM)(Ben-Dor et al., 2000), we tested genes, one at a time, to see whether their expression 
differentiates the two groups of samples that were identified by CTWC. This step provides an 
extended set of genes, which is now used to identify, in an unsupervised manner, samples that 
belong to classes of relatively high expression. This procedure is reminiscent in spirit of the 
signature method (Ihmels et al., 2002), albeit the latter uses a known set of genes (or 
conditions) as it's seed and does not switch to supervised statistical tests to refine the genes it 
found.  
 For binary class comparisons we used a non-parametric statistical test,  TNoM (Ben-
Dor et al., 2000), which tests whether the expression value of a certain gene can predict the 
class of the sample. An informative gene is expected to have quite different values in the two 
classes, and thus we should be able to separate these by a threshold value. TNoM provides an 
appropriate score according to the quality of separation. For each score we calculate its P-
value, as describe in Ben-Dor et al(Ben-Dor et al., 2000).  In order to control contamination 
with false positive genes associated with multiple comparisons we used the method of 
Benjamini and Hochberg(Benjamini & Hochberg, 1995) that bounds the average false 
 18
discovery rate (FDR); namely, the fraction of false positives among the list of differentiating 
genes.  
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Table 1. Genes that separate the ALL samples into two subgroups 
 
Gene 
Probe ID 
Title Gene 
Symbol 
TEL-AML1 
CTWC 
step (i) a
TNoM 1 
step(ii)b 
( P value) 
 
TNoM 2 
step(iv)c 
(P value) 
36927_at chromosome 1 open reading frame 29 C1orf29 + 0.000115 6.69E-35 
925_at interferon, gamma-inducible protein 30 IFI30 +  2.51E-32 
915_at 
(32814_at) 
interferon-induced protein with tetratricopeptide 
repeats 1 
IFIT1 + 6.06E-06 2.51E-32 
37641_at interferon-induced protein 44 IFI44 + 6.06E-06 4.44E-31 
37014_at myxovirus (influenza virus) resistance 1 MX1 + 6.06E-06 7.40E-30 
38584_at interferon-induced protein, tetratricopeptide 
repeats 4 
IFIT4 + 0.000115 1.17E-28 
1107_s_at 
(38432_at) 
interferon, alpha-inducible protein (clone IFI-15K) G1P2 + 6.06E-09 3.41E-25 
38389_at 2',5'-oligoadenylate synthetase 1, 40/46kDa OAS1 + 0.000115 4.43E-24 
39263_at 
(39264_at) 
2'-5'-oligoadenylate synthetase 2, 69/71kDa OAS2 + 0.000115 5.51E-23 
38014_at adenosine deaminase, RNA-specific ADAR  6.06E-09 6.57E-22 
38517_at interferon-stimulated transcription factor 3, gamma ISGF3G   8.76E-19 
1358_s_at   + 6.06E-09 8.35E-16 
38662_at Homo sapiens, clone IMAGE:4074138, mRNA  
sequence 
  6.06E-06 7.67E-15 
37360_at lymphocyte antigen 6 complex, locus E LY6E  6.06E-06 3.94E-11 
35718_at SP110 nuclear body protein SP110   2.35E-09 
33339_g_at 
(32860_g_at) 
signal transducer and activator of transcription 1, 
91kDa 
STAT1 +  1.74E-08 
464_s_at interferon-induced protein 35 IFI35  0.000115 8.77E-07 
914_g_at  v-ets erythroblastosis virus E26 oncogene like (avian) ERG   5.98E-06 
 25
(36383_at) 
40054_at KIAA0082 protein KIAA0082   5.98E-06 
37352_at 
(3753_g_at) 
nuclear antigen Sp100 SP100 + 6.06E-06 5.98E-06 
34947_at 
(41472_at) 
apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3G 
APOBEC3G   3.97E-05 
36845_at nuclear matrix protein NXP-2 NXP-2   3.97E-05 
40505_at ubiquitin-conjugating enzyme E2L 6 UBE2L6  0.000115 3.97E-05 
41841_at Homo sapiens clone 23718 mRNA sequence    0.000257 
39061_at bone marrow stromal cell antigen 2 BST2   0.000257 
32800_at retinoid X receptor, alpha RXRA   0.000257 
38805_at TGFB-induced factor (TALE family homeobox) TGIF   0.000257 
890_at ubiquitin-conjugating enzyme E2A (RAD6 homolog) UBE2A   0.000257 
40852_at tudor repeat associator with PCTAIRE 2 PCTAIRE2
BP 
+   
32775_r_at phospholipid scramblase 1 PLSCR1 +   
36412_s_at interferon regulatory factor 7 IRF7 + 2.36E-07  
41745_at interferon induced transmembrane protein 3 (1-8U) IFITM3  6.06E-06  
676_g_at 6-pyruvoyltetrahydropterin synthase PTS  0.000115  
1184_at 
(41171_at) 
proteasome (prosome, macropain) activator subunit 2 
(PA28 beta) 
PSME2  6.06E-06  
 a In the 'TEL-AML CTWC step (i)' column we mark by + the genes that were obtained by the initial CTWC (step 
(i) of our analysis); two out of the 16 probe-sets correspond to the same gene and hence only 15 genes are marked.  
bThe 'TNoM1 step (ii)' column gives P-values of the genes that separate 8 versus 71 TEL-AML1 samples 
according to the TNoM test, at FDR=0.05. Only 19 genes are indicated (out of 23 probe-sets), again because of 
multiple representations. cThe 'TNoM2 step (iv)' column indicates 28 probe sets that separate all the ALLs into 
two subgroups of 50 versus 285 samples (see  text). The genes that are known to be part of the interferon-
JAK/STAT pathway are in bold face. In cases when two probe sets represent the same gene symbol, the lower p-
value was taken.   
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 Table 2. The number of samples from each subtype in the Yeoh et al.(Yeoh et al., 2002) dataset and in the 
new subgroup 
  
Subtype name Number  
of samples 
Number 
in subgroup 
Hyperdip>50 65 24 
TEL-AML1 79 10     
Pseudodip 29 4 
Normal 19 4 
Hyperdip 47-50 23 3 
T-ALL 45 2 
BCR-ABL 16 2 
MLL 21 1 
Hypodip 11 0 
E2A-PBX1 27 0 
Total: 335 50 
   
Novel subtype (as found 
by Yeoh et al.) 
14 6 
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Table 3. Datasets that were examined by the CTWC algorithm using the interferon related set of genes 
 
Datasets Type of samples Overexpressed samples  
Golub et al.(Golub et al., 
1999) 
60 leukemic samples of ALL and AML 5 samples, 4 of them are MLL 
Armstrong et 
al.(Armstrong et al., 2002) 
72 leukemic samples: 24 ALL, 20 AML 
and 28 MLL 
7 samples (4 ALL, 2 MLL, 1 AML) 
Rozovskia et 
al.(Rozovskaia et al., 2003) 
60 leukemic samples of ALL, MLL and 
CD10- ALLs 
6 MLL and ALL 
Shipp et al.(Shipp et al., 
2002) 
Lymphoma samples from 58 DLBCL 
patients and 19 FL patients 
None  
Welsh et al. 
(Prostate)(Welsh et al., 
2001) 
55 prostate cancer samples None  
Singh et al.(Singh et al., 
2002)  
102 prostate cancer samples None  
Staunton et al.(Staunton et 
al., 2001) 
60 samples from various types of 
cancer 
Poor separation of 3 samples (taken from breast cancer, 
renal cancer and leukemia patients)  
Ramaswamy et 
al.(Ramaswamy et al., 
2001) 
280 samples from various types of 
cancer 
7 samples: 1 lymphoma samples, 2 leukemia AML 
samples, 1 breast cancer sample , 1 bladder cancer 
sample and 2 samples taken from normal peripheral 
blood 
Welsh et al. (ovary)(Welsh 
et al., 2001) 
49 ovary cancer samples ~10 samples  
Bhattacharjee et 
al(Bhattacharjee et al., 
2001)  
203 Lung cancer samples 6 samples. Other ~40 samples expressed intermediate 
mRNA level. 
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Figure 1. Expression values of the cluster of 16 genes, found by CTWC, in 79 TEL-AML1 
samples. The values are centered (mean expression of each gene = 0) and normalized (std = 1). 
These genes are overexpressed in a group of 8 (out of 79) TEL-AML1 samples. 
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Figure 2. Expression values of the group of 23 genes in 335 ALL samples. The values are 
centered (mean expression of each gene = 0) and normalized (std = 1). These genes are 
correlated and overexpressed in a group of 50 ALL samples, that consist mainly of 
hyperdiploid>50 and TEL-AML1 subtypes. 
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Figure 3. Expression values of 12 genes in 96 breast cancer samples (van 't Veer et al., 2002). 
The values are centered (mean expression of each gene = 0) and normalized (std = 1). 
Approximately 40% of the samples, to the right of the black dotted line, overexpress these 
genes. The differentiating genes are: IFI35, IFI30, STAT1, LY6E, OAS2, OAS1, IFIT1, 
UBE2L6, IFIT4, PLSCR1, IRF7, MX1. 
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